Extended-spectrum β-lactamase-producing Shigella strains in Israel, 2000-2004

V. Vasilev*, R. Japheth, R. Yishai, N. Andorn, L. Valinsky, S. Navon-Venezia, I. Chmelnitsky, Y. Carmeli, D. Cohen

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

19 Scopus citations


Routine susceptibility testing of 5,616 Shigella isolates at the National Shigella Reference Centre in Israel over a 5-year period (2000-2004) revealed resistance to ceftriaxone in one strain of Shigella boydii 2 and in two strains each of Shigella flexneri 2a, S. flexneri 6, and Shigella sonnei. All seven isolates were confirmed as producers of extended-spectrum β-lactamase (ESBL) by the combination disk method, the Vitek 1 system, and a modification of the double-disk synergy test, which is based on the inhibitory properties of clavulanic acid, tazobactam, and sulbactam. Tazobactam had the strongest effect in all seven strains. Molecular characterization of the ESBLs identified CTX-M-type enzymes, consisting of the CTX-M-9 group (n=3), CTX-M-3 (n=2), CTX-M-39 (n=1), and CTX-M-2 group (n=1). Three of the strains also carried bla-OXA genes and a bla-TEM gene. Although the prevalence of ESBLs in this study was low, further research is needed on the spread and transfer of resistance genes, both in hospitals and in the community.

Original languageEnglish
Pages (from-to)189-194
Number of pages6
JournalEuropean Journal of Clinical Microbiology and Infectious Diseases
Issue number3
StatePublished - Mar 2007


Dive into the research topics of 'Extended-spectrum β-lactamase-producing Shigella strains in Israel, 2000-2004'. Together they form a unique fingerprint.

Cite this